Clinical Trial Update: Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast [NA]

View source ↗

Summary

This clinical trial update compares fulvestrant and tamoxifen in postmenopausal women undergoing surgery for ductal carcinoma in situ of the breast.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ of the Breast

Drugs mentioned

• Faslodex (fulvestrant)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Breast Cancer | NA | Status: UNKNOWN